 SAN DIEGO--BUSINESS WIRE--- GOSS--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamers Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamers Senior Vice President, Research Translational Biology 